Karyopharm
Newton, US · 4 known investors
Find your way into Karyopharm
744 people in our graph share verified history with the Karyopharm team — schools, employers, funds. One of them is your warm intro.
Seth Lieblichunlockedknows Richard Paulson · together at Amgen (overlapped)
×5knows the team · via Duke University
×3knows the team · via Amgen
knows the team · via Penn Medicine, University of Pennsylvania Health System
×2knows the team · via AbbVie
Karyopharm is a pharmaceutical company developing drugs based on its SINE (Selective Inhibitor of Nuclear Export) technology, with medicines targeting cancers including multiple myeloma and diffuse large B-cell lymphoma. It serves patients and healthcare providers in oncology.
Founders & leadership
SP
Stuart PoultoninExecutiveStuart Poulton is Executive Vice President and Chief Development Officer at Karyopharm Therapeutics, overseeing global clinical development operations. He previously led strategic portfolio management at AbbVie and brings experience spanning drug development across oncology, bone health, cardiovascular, diabetes, anti-infectives, immunology, and neuroscience throughout his pharmaceutical industry career.
MM
Michael ManoinExecutive
RR
Reshma RangwalainExecutiveRangwala holds an MD with specialization in medical oncology and a doctorate in cell biology/neurosciences, with extensive clinical development experience in oncology and immunology spanning multiple cancer indications including lung, hepatocellular, ovarian, and melanoma, as well as expertise in immunotherapy, companion diagnostics, and regulatory interactions with health agencies.
RP
Richard PaulsoninExecutiveRichard Paulson has spent over 25 years in the life sciences industry in various roles across global organizations. He serves as Executive Officer and Director at Karyopharm, a pharmaceutical company developing SINE technology-based medicines for oncology indications including multiple myeloma and diffuse large B-cell lymphoma.
SM
Stephen MitchenerinExecutive
MM
Michael MasoninExecutive
PH
Peter HonigNamed on SEC filing
CS
Chen SchorNamed on SEC filing
Board
DR
Deepika R. PakianathanBoard director
BE
Barry E. GreeneBoard director
MR
Mansoor Raza MirzaBoard director
GG
Garen G. BohlinBoard director
Investors · 4
Funding
SEC filings, press & company announcements$165M disclosed across 1 of 2 rounds · 2022–2026
- Undisclosed amountprivate placementMar 2026Source ↗
▶$165MraisedDec 2022 · 33 investors · PharmaceuticalsRule 506(b)
▶$165MraisedDec 2022 · 33 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Peter HonigDirector
- Barry E. GreeneDirector
- Stuart PoultonExecutive Officer
- Michael ManoExecutive Officer
- Reshma RangwalaExecutive Officer
- Richard PaulsonExecutive Officer, Director
- Deepika R. PakianathanDirector
- Chen SchorDirector
- Stephen MitchenerExecutive Officer
- Michael MasonExecutive Officer
- Mansoor Raza MirzaDirector
- Garen G. BohlinDirector
- Christy J. OligerDirector
- Sohanya ChengExecutive Officer
- Offering amount
- $165M
- Amount sold
- $165M
- Sales commissions
- $9.9M
- Placement agents
- Robert W. Baird & Co. Incorporated, Piper Sandler & Co., Jefferies LLC, Barclays Capital, Inc., H.C. Wainwright & Co. LLC
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlap
Seeking Alpha37 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Robinhood36 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Kite Pharma35 shared keywordsKite develops CAR T-cell therapies that engineer a patient's own immune cells to target and destroy cancer cells. The company focuses on cell therapy treatments for cancers such as diffuse large B-cell lymphoma.
Companies competing with Karyopharm for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2018 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $225K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Karyopharm do?
- Karyopharm is a pharmaceutical company developing drugs based on its SINE (Selective Inhibitor of Nuclear Export) technology, with medicines targeting cancers including multiple myeloma and diffuse large B-cell lymphoma. It serves patients and healthcare providers in oncology.
- Who are Karyopharm's investors?
- Karyopharm's investors include Avoro Capital Advisors, Foresite Capital, HEALTHCARE ROYALTY PARTNERS, RA Capital.
- How much funding has Karyopharm raised?
- Karyopharm has disclosed $165M raised across 1 of its 2 known rounds.
- Where is Karyopharm headquartered?
- Karyopharm is headquartered in Newton, US.